InspireMD $11M Debt Financing
InspireMD entered into amendments with holders of its Series J and Series K warrants to align their exercise triggers with the anticipated Q4 2026 FDA approval of the CGuard Prime 80 cm. The amendments modify the exercise price to $0.7674 per share for approximately 14.3 million underlying shares, potentially providing up to $11 million in gross proceeds to fund the product launch. The new expiration date is set for 20 trading days following the announcement of FDA approval or May 15, 2028.
- Value
- $11M